Parathyroid hormone is not an inhibitor of lipoprotein lipase activity.
The reduced lipoprotein lipase (LPL) activities in uraemia are reflected by increased serum triglyceride concentrations and reduced HDL cholesterol concentrations. Both hyperparathyroidism and circulating inhibitor(s) of LPL have been associated with the disturbances of lipid metabolism in uraemia. The aim of the present study was to investigate if parathyroid hormone (PTH) had an inhibitory effect on LPL activity. Plasma post-heparin LPL activities, plasma LPL inhibitory activities, serum PTHintact and serum PTHC-terminal concentrations were analysed in 20 patients on haemodialysis and 20 healthy controls. The effects of purified, human PTHintact and a carboxyterminal fragment of PTH (PTH39-84) on LPL activities in post-heparin plasma from healthy individuals and on the enzyme activity of purified, bovine milk LPL, activated with apolipoprotein CII, were studied. Patients had significantly higher plasma LPL inhibitory activities than controls, but there was no correlation between plasma LPL inhibitory activities and serum PTH concentrations. Neither PTHintact nor PTH39-84 had a significant effect on LPL activities in vitro. Thus there was no evidence of a direct inhibition of LPL activity by PTH under the present in-vivo or in-vitro conditions.
Arnadottir
M
M
Department of Nephrology, University Hospital, Lund, Sweden.
Nilsson-Ehle
P
P
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D008071:Lipoprotein Lipase / Q000037:antagonists & inhibitors / Q000097:blood*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood* / Q000494:pharmacology; D010446:Peptide Fragments / Q000494:pharmacology; D006435:Renal Dialysis; D014511:Uremia / Q000097:blood* / Q000209:etiology / Q000628:therapy
D008074:Lipoproteins; D010281:Parathyroid Hormone; D010446:Peptide Fragments; D008071:Lipoprotein Lipase